REQ-0000020479: what clinicians are saying
nivolumab in muscle-invasive bladder cancer · NCT03993249 ↗ · Phase 2 · Hellenic GenitoUrinary Cancer Group
The clinicians cited read REQ-0000020479 as supporting phase III testing because of reported survival gains, rather than justifying routine use. A radiation oncologist reports that the local-control benefit was not statistically significant; another questions cisplatin as the sole chemotherapy agent. The statements leave the severity and management burden of added immune adverse events unclear. The sources reviewed for this edition place the phase II results at ESTRO2025.
Created with AI · how we check it
- edition 1
- commentary checked Nov 22, 2026
- 34 verified statements
This edition $750, with MCP access for your AI agent. Get this report
6 findings, and what sits behind each
01. Phase II efficacy: what most speakers highlight; some seek phase III testing
2 of the report's 7 cited clinicians · 10 statements from 6 speakers in 6 sources, 1 of them a podcast or video · 8 passages
Limitations recorded: 2.
Draws on: Design and conduct, Secondary endpoint: Median overall survival (OS), The comparison, Population and setting.
02. Survival: what speakers note; one awaits primary local-control data
2 of the report's 7 cited clinicians · 6 statements from 5 speakers in 5 sources, 1 of them a podcast or video · 5 passages
Limitations recorded: 3.
Draws on: Secondary endpoint: Median overall survival (OS), Secondary endpoint: Bladder cancer failure-free (BCFF) rates, Primary endpoint: Locoregional control rate, Secondary endpoint: Incidence Rate of treatment-related adverse event (safety and tolerability), Safety and tolerability, Design and conduct.
03. Control arm: what speakers say
2 of the report's 7 cited clinicians · 5 statements from 2 speakers in 3 sources · 3 passages
Limitations recorded: 2.
Draws on: The comparison, Design and conduct.
04. Safety signals: what speakers highlight; a clinician notes more immune toxicity
1 of the report's 7 cited clinicians · 6 statements from 4 speakers in 5 sources · 6 passages
Limitations recorded: 2.
Draws on: Safety and tolerability, Secondary endpoint: Incidence Rate of treatment-related adverse event (safety and tolerability), Secondary endpoint: Median overall survival (OS), Secondary endpoint: Bladder cancer failure-free (BCFF) rates.
05. Chemotherapy compliance: most clinicians await S1806; one notes agents differ
2 of the report's 7 cited clinicians · 4 statements from 3 speakers in 2 sources · 4 passages
Limitations recorded: 3.
Draws on: Design and conduct, Secondary endpoint: Median overall survival (OS), The comparison, Safety and tolerability.
06. MIBC label: what speakers say
2 of the report's 7 cited clinicians · 4 statements from 3 speakers in 3 sources, 1 of them a podcast or video · 5 passages
Limitations recorded: 2.
Draws on: Population and setting, Design and conduct.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
2 of the report's 7 cited clinicians
Phase II efficacy: what most speakers highlight; some seek phase III testing
10 statements from 6 speakers in 6 sources, 1 of them a podcast or video
5 of the 6 named speakers in this finding hold this view; 3 of the 6 hold its caveat, “some seek phase III testing”
- 10
- statements
- 8
- passages
- 6
- sources
- 6
- speakers
What the statements areViews 9Questions and uncertainty 1Clinical experience 0Comparisons 0Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 10Giving context 0Recorded with the findingLimitations: 2
5 posts and articles · 1 podcast or video
Draws on: Design and conduct, Secondary endpoint: Median overall survival (OS), The comparison, Population and setting.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
Abbreviations (4)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival.
The full REQ-0000020479 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say a randomized phase III trial must establish about overall survival before they would add nivolumab to chemoradiotherapy for muscle-invasive bladder cancer in patients not undergoing cystectomy?
From finding F1 (10 statements from 6 speakers in 6 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 17commentary sources screened
- 14sources cited by verified statements
- 14named in screened sources
- 14speakers cited in the report
- 13cited speakers with a verified identity
7 cited clinicians, speakers with a confirmed clinical role, of them 7 physicians. By role and specialty:
- 6 physician, Radiation oncology
- 1 physician, Medical oncology
Also in the sources: 3 organizational or shared accounts, not counted as people.
- 34verified statements, each linked to its source
- 13of them from speakers with a confirmed clinical role
- 6findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 34 | Paid |
| Who said each statement: the cited speakers | 14 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 13 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 14 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
11 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Locoregional control rate | 2 | 2 |
| Secondary endpoint: Incidence Rate of treatment-related adverse event (safety and tolerability) | 5 | 5 |
| Secondary endpoint: Bladder cancer failure-free (BCFF) rates | 3 | 3 |
| Secondary endpoint: Median overall survival (OS) | 10 | 10 |
| Secondary endpoint: Assessment of the effect of the combined treatment on the quality of lifeno commentary found | 0 | 0 |
| Population and setting | 5 | 4 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 8 | 5 |
| Safety and tolerability | 6 | 5 |
| Design and conduct | 11 | 5 |
| Phase III validation and clinical adoption | 14 | 10 |
| Chemotherapy compliance and interpretation of forthcoming studies | 6 | 3 |
| Endpoint terminology and proposed distant-relapse explanation | 8 | 7 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
34 verified statements from 14 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 7 statements · 21% | ||||
| YouTube | 7 | 2 | 2 | |
| Posts · 26 statements · 76% | ||||
| X threads | 26 | 11 | 15 | |
| Primary sources · 1 statement · 3%cited for context, not screened | ||||
| Registry | 1 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 8 / quarter
- Screened window
- Dec 9, 2020 → Nov 9, 2026
- Cited window
- Sep 16, 2024 → Nov 9, 2026
- Retrieved
- Nov 22, 2026
The trial
from ClinicalTrials.gov- Title
- Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study
- Registry
- NCT03993249
- Study IDs
- REQ-0000020479
- Sponsor
- Hellenic GenitoUrinary Cancer Group
- Design
- Phase 2 · Interventional, randomized, parallel
- Status
- Unknown
- Enrollment
- 78 estimated
- Registered
- 2019-06-20
- Start
- 2019-05-28 actual
- Primary completion
- 2022-08 estimated
- Primary endpoint
- Locoregional control rate
- Interventions
- 2 registered
More on: Urothelial carcinoma, nivolumab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 8 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 121 sources about other trials or topics are not included.
- No full protocol was listed in the reviewed registry material, and no results publication was available for the exact trial. The registry evidence describes planned methods, not observed outcomes.
- Several relevant statements describe the study’s regimen, population or clinical question without naming NCT03993249. They inform interpretation of the decision but should not automatically be treated as independently identified reports of this trial’s results.
Show all 8 known gaps +Fewer −
- Interview publication dates and X post dates do not establish presentation dates or a change of opinion. Expectations about endpoint maturity and forthcoming studies are preserved at the time they were expressed.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The reviewed statements do not resolve detailed endpoint equivalence, exact treatment-delivery differences, immune-event burden or quality-of-life effects.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 22, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. REQ-0000020479 (NCT03993249): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/req-0000020479-nct03993249
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "REQ-0000020479" (NCT03993249), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "req-0000020479-nct03993249". If you cannot make requests, read https://www.erudio.com/reports/req-0000020479-nct03993249.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT03993249", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT03993249 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/req-0000020479-nct03993249.json
curl https://www.erudio.com/reports/req-0000020479-nct03993249.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "req-0000020479-nct03993249" })release 339e9e25be2557cde8b9698e238b4e447f4597b4d7684a0565c2281e708e3160
Questions
How much does the REQ-0000020479 report cost?
One edition costs $750 (Focused · 34 verified statements · 13 from 7 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the REQ-0000020479 report cover?
34 statements from 14 sources (2 videos, 11 posts, 1 registry record), 13 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the REQ-0000020479 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "req-0000020479-nct03993249" }) previews it and create_order({ "report": "req-0000020479-nct03993249", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the REQ-0000020479 report?
Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.